IP Library Granted Patent US 7,282,178
Granted Patent B2
US 7,282,178 · App. 11/442,789 · Granted Oct 16, 2007

Composition and method for cleaning lipid deposits on contact lenses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,282,178
App. No.
11/442,789
Granted
Oct 16, 2007
Kind
B2
Abstract

This invention is directed to an aqueous composition and methods for clean lipid deposits on contact lenses. In particular, a combination of non-ionic surfactants, branched and/or straight poly(ethylene oxide-propylene oxide) (PEO-PPO) block copolymers having HLB value greater than or equal to 18, with an additional straight poly(ethylene oxide-propylene oxide) (PEO-PPO) block copolymers having HLB value less than or equal to 15, has been found to improve the lipid cleaning properties of an aqueous composition for contact lenses and prevent the overgrowth of harmful bacteria, yeast and molds without adversely affecting the comfort or safety in terms of the level of toxicity to eye tissue.

Claims (37)

1. An aqueous composition for cleaning lipid deposits or for minimizing lipid deposition on a contact lens, said composition comprising:

a poloxamine having an HLB value greater than or equal to 18;

a poloxamer having an HLB value less than or equal to 15, and is present in an amount effective to improve the lipid cleaning effect of the composition;

a straight chain polyether surfactant having an HLB value greater than or equal to 18;

one or more antimicrobial agents present in an amount effective to disinfect or preserve the composition; and

a buffering agent, and an osmolality adjusting agent, wherein the osmolality adjusting agent is present to provide an osmolality of from 200 to 400 mOsm/kg.

2. The aqueous composition of claim 1 , wherein the weight ratio of the poloxamine to the straight chain polyether surfactant having an HLB value greater than or equal to 18 is about one to two.

3. The aqueous composition of claim 1 , wherein the poloxamine is selected from the group consisting of poloxamine 707, poloxamine 908, poloxamine 1107, poloxamine 1307 and poloxamine 1508.

4. The aqueous composition of claim 1 wherein the straight chain polyether surfactant having an HLB value greater than or equal to 18 is selected from the group consisting of poloxamer 105, poloxamer 108, poloxamer 188, poloxamer 217, poloxamer 237, poloxamer 238, poloxamer 288, poloxamer 338 and poloxamer 407.

5. The aqueous composition of claim 1 , wherein the poloxamer having an HLB value less than or equal to 15 are poloxamer 403 and poloxamer 335.

6. The aqueous composition of claim 1 , wherein the poloxamer having an HLB value less than or equal to 15 is present from about 0.01 weight percent to 2 weight percent.

7. The aqueous composition of claim 1 , wherein the buffer agent is selected from the group consisting of borate buffers, citrate buffers, aminoalcohol buffers, Good buffers, phosphate buffers, and mixtures thereof to maintain a pH from about 6 to about 8.

8. A method of cleaning lipid deposits or minimizing lipid deposition on a contact lens in the eye, the method comprising administering aqueous eye drop to the eye, the composition comprising:

(a) a poloxamine having an HLB value greater than or equal to 18; and

(b) a poloxamer having an HLB value less than or equal to 15, and is present in an amount effective to improve the lipid cleaning effect of the composition;

a straight chain polyether surfactant having an HLB value greater than or equal to 18;

one or more antimicrobial agents present in an amount effective to preserve the composition; and

a buffering agent, and an osmolality adjusting agent, wherein the osmolality adjusting agent is present to provide an osmolality of from 200 to 400 mOsm/kg.

9. The method of claim 8 , wherein the weight ratio of the poloxamine to the straight chain polyether surfactant having an HLB value greater than or equal to 18 is about one to two.

10. A method of cleaning lipids and/or prevent lipid deposition on a contact lens while worn on an eye comprising:

(i) soaking prior to placement on an eye contact lens in an aqueous composition comprising:

(a) a poloxamine having an HLB value greater than or equal to 18;

a straight chain polyether surfactant having an HLB value greater than or equal to 18; and

a poloxamer having an HLB value less than or equal to 15, and is present in an amount effective to improve the lipid cleaning effect of the composition, and

(ii) directly placing the treated contact lens in an eye of the wearer.

11. The method of claim 10 , wherein the weight ratio of of the poloxamine to the straight chain polyether surfactant having an HLB value greater than or equal to 18 is about one to two.

12. The aqueous composition of claim 1 , wherein the one or more antimicrobial agents is selected from the group consisting of 4-tris(2-hydroxyethyl) ammonio]-2-butenyl-ω-[tris(2-hydroxyethyl)ammonio]dichloride, poly(hexamethylene biguanide) and alexidine.

13. The method of claim 8 , wherein the one or more antimicrobial agents is selected from the group consisting of 4-tris(2-hydroxyethyl)ammonio]-2-butenyl-ω-[tris(2-hydroxyethyl)ammonio]dichloride, poly(hexamethylene biguanide) and alexidine.

14. The aqueous composition of claim 1 , further comprising a wetting agent selected from the group consisting of poly(vinylpyrrolidone), hydroxypropylmethyl cellulose and propylene glycol.

15. The method of claim 8 , wherein the composition further comprises a wetting agent selected from the group consisting of poly(vinylpyrrolidone), hydroxypropylmethyl cellulose and propylene glycol.

16. The aqueous composition of claim 1 , wherein the poloxamer having an HLB value less than or equal to 15 is present from 0.01 wt. % to 0.25 wt. %.

17. The method of claim 8 , wherein the poloxamer having an HLB value less than or equal to 15 is present from 0.01 wt. % to 0.25 wt. %.

18. The method of claim 10 , wherein the poloxamer having an HLB value less than or equal to 15 is present from 0.01 wt. % to 0.25 wt. %.

19. The method of claim 8 , wherein the poloxamer having an HLB value less than or equal to 15 is present from about 0.01 wt. %to 2 wt. %.

20. The method of claim 10 , wherein the poloxamer having an HLB value less than or equal to 15 is present from about 0.01 wt. %to 2 wt. %.

21. The method of claim 10 , wherein the composition further comprises one or more antimicrobial agents selected from the group consisting of 4-tris(2-hydroxyethyl)ammonio]-2-butenyl-ω-[tris(2-hydroxyethyl)ammonio]dichioride, poly(hexamethylene biguanide) and alexidine.

22. The method of claim 10 , further comprising a wetting agent selected from the group consisting of poly(vinylpyrrolidone), hydroxypropylmethyl cellulose and propylene glycol.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Mar 26, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC
To: CREDIT SUISSE
Reel/Frame 020733/0765 →
SECURITY AGREEMENT Recorded Nov 16, 2007
From: BAUSCH & LOMB INCORPORATED; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; IOLAB CORPORATION; RHC HOLDINGS, INC.; WP PRISM, INC.
To: CREDIT SUISSE
Reel/Frame 020122/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2006
From: SALAMONE, JOSEPH C.; BORAZJANI, ROYA; BARNIAK, VICKI; MANCHESTER, ROBERT; MCCANNA, DAVID
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 017952/0029 →